Global Hemophilia Market Report: Insights, Trends and Forecast (2019-2023)

Global Hemophilia Market Report: Insights, Trends and Forecast (2019-2023)

  • Koncept Analytics
  • July 2019
  • Pharmaceutical
  • 106 pages

Report Description

1
1

The global hemophilia market is estimated to reach US$12.98 billion in 2023, holding a CAGR of 6.21% in the duration spanning 2018-2023. The factors such as rise in diagnoses rate of hemophilia, rise in global healthcare expenditure and shifting focus to extended half-life (EHL) therapies are expected to drive the growth of the global hemophilia market. However, growth of the industry will be challenged by high price of treatment and reluctance to switch to new therapies. A few notable trends include shifting focus to Extended Half Life (EHL) therapies, development of novel hemophilia treatments and popularity of gene therapy.

The global hemophilia market comprises of two major segments: hemophilia A and hemophilia B. hemophilia A is four time prevalent than hemophilia B. The growing incidences of hemophilia A at vast rate has driven the increased demand for anti-hemophilia A or clotting factor VIII drugs. The pharmaceutical industry is flooded with drugs to be used in the treatment of type A, and thereby providing scope for the expansion of the global hemophilia market.

The fastest growing regional market in the hemophilia space is the U.S. due to High prevalence of hemophilia, coupled with rising inclination toward prophylaxis treatment. Rise in the population of hemophilia patients, is augmenting the need for more significant treatment methods. A lot of anti-hemophilia products are available in the market and several drugs are still in their late stage clinical process by large pharmaceutical firms. Furthermore, The U.S. and Europe are the highly established premium markets that contribute to considerable shares in the global hemophilia market.

Scope of the report:

  • The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B.
  • The major regional markets (the U.S. and Europe) have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Bayer Group, Sanofi S.A., Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail.

Key Target Audience:

  • Hemophilia Drugs Manufacturers
  • Raw Material Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms 
  • Investment Banks
  • Government Bodies & Regulating Authorities

Have query on this report?

Make an Enquiry

Table of Content

1. Market Overview
1.1 Hemophilia 
1.2 Types of Hemophilia 
1.3 Signs & Symptoms 
1.4 Diagnosis of Hemophilia
1.5 Treatment of Hemophilia

2. Global Market Analysis
2.1 Global Hemophilia Market by Value 
2.2 Global Hemophilia Market Forecast by Value 
2.3 Global Hemophilia Market by Treatment Regimen
2.4 Global Hemophilia Market by Type
2.4.1 Global Hemophilia A Market Forecast by Value 
2.4.2 Global Hemophilia A Market by Severity
2.4.3 Global Hemophilia A Market by Treatment Type
2.4.4 Global Hemophilia A Market by Treatment Regimen
2.4.5 Global Hemophilia B Market Forecast by Value 
2.4.6 Global Hemophilia B Market by Severity 
2.4.7 Global Hemophilia B Market by Treatment Type
2.4.8 Global Hemophilia B Market by Treatment Regimen

3. Regional Market Analysis
3.1 The U.S. 
3.1.1 The U.S. Hemophilia Market by Value 
3.1.2 The U.S. Hemophilia Market Forecast by Value 
3.1.3 The U.S. Hemophilia Market by Type 
3.1.4 The U.S. Hemophilia A Market Forecast by Value
3.1.5 The US Hemophilia A Market-Treated Patient Volume Forecast
3.1.6 The US Hemophilia A Market-Severe Patients on Prophylactic Therapy
3.1.7 The US Hemophilia A Market-Severe Patients on On-Demand Therapy
3.1.8 The US Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy
3.1.9 The US Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy
3.1.10 The US Hemophilia B Market Forecast by Value 
3.1.11 The US Hemophilia B Market- Treated Patients Volume Forecast 
3.1.12 The US Hemophilia B Market- Severe Patients on Prophylaxis Therapy
3.1.13 The US Hemophilia B Market- Severe Patients on On-Demand Therapy
3.1.14 The US Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy
3.1.15 The US Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy
3.2 Europe 
3.2.1 Europe’s Hemophilia Market- Patient Volume Forecast
3.2.2 Europe’s Hemophilia A Market- Patient Volume Forecast
3.2.3 Europe’s Hemophilia B Market- Patient Volume Forecast

4. Market Dynamics
4.1 Growth Drivers 
4.1.1 Increased Focus on Prophylactic Treatment 
4.1.2 Increasing Diagnosis Rate 
4.1.3 Rise in Global Healthcare Expenditure
4.2 Key Trends & Development
4.2.1 Shifting Focus to Extended Half Life Therapies
4.2.2 Development of Novel Hemophilia Treatments
4.2.3 Popularity of Gene Therapy
4.3 Challenges 
4.3.1 High Cost of Treatment 
4.3.2 Reluctance to Switch to New Therapies

Signs & Symptoms of Hemophilia 
Extended Half Life Products (2018)
Development of New Novel Hemophilia Treatments (2018)
Hemophilia Gene Therapy Candidates (2018)
Key Players – Main Anti-Hemophilia Products
Key Players – Revenue Comparison (2018)
Key Players – Market Capital Comparison (2019)
Major Products Developed by Pfizer Inc. (2018) 
Major Products Developed by Bayer Group (2018) 
Novo Nordisk Product Pipeline (2018)

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074